Neoadjuvant Radiotherapy Versus Surgery Alone for Stage II/III Mid-low Rectal Cancer With or Without High-risk Factors A Prospective Multicenter Stratified Randomized Trial

被引:27
|
作者
Deng, Xiangbing [1 ]
Liu, Ping [2 ]
Jiang, Dan [3 ]
Wei, Mingtian [1 ]
Wang, Xin [4 ]
Yang, Xuyang [1 ]
Zhang, Yuanchuan [5 ]
Wu, Bing [6 ]
Liu, Yanjun [5 ]
Qiu, Meng [4 ]
Zhuang, Hua [7 ]
Zhou, Zongguang [1 ]
Li, Yunfeng [2 ]
Xu, Feng [4 ]
Wang, Ziqiang [1 ]
机构
[1] Sichuan Univ, West China Hosp, Dept Gastrointestinal Surg, Chengdu, Peoples R China
[2] Kunming Med Univ, Affiliated Hosp 3, Colorectal Canc Clin Res Ctr, Kunming, Yunnan, Peoples R China
[3] Sichuan Univ, West China Hosp, Dept Pathol, Chengdu, Peoples R China
[4] Sichuan Univ, West China Hosp, Dept Abdominal Canc, Canc Ctr, Chengdu, Peoples R China
[5] Third Peoples Hosp Chengdu, Dept Gen Surg, Chengdu, Peoples R China
[6] Sichuan Univ, West China Hosp, Dept Radiol, Chengdu, Peoples R China
[7] Sichuan Univ, West China Hosp, Dept Ultrasound, Chengdu, Peoples R China
关键词
local recurrence; rectal cancer; risk stratification; short-course radiotherapy; total moserectal excision;
D O I
10.1097/SLA.0000000000003649
中图分类号
R61 [外科手术学];
学科分类号
摘要
Objective: The aim of this study was to compare stage II/III rectal cancers with or without high-risk factors, and evaluate the effect of neoadjuvant radiotherapy (NRT) in these 2 cohorts. Background: NRT is often used in stage II/III rectal cancers to improve local control, while not affecting overall survival. However, good-quality surgery without NRT may also achieve good local control in selected patients. Methods: According to risk-stratification criteria and clinical staging, consecutive eligible participants of stage II/III rectal cancer were preoperatively classified into patients with (high-risk) or without (low-risk) high-risk factors. Both groups were respectively randomized to receive either short-course radiotherapy (SCRT) + total mesorectal excision (TME) or TME alone, forming the following 4 groups: high-risk patients with (HiR) or without (HiS) radiation, and low-risk patients with (LoR) or without (LoS) radiation. The primary endpoint was local recurrence. The secondary endpoints included overall survival, disease-free survival, distant recurrence, quality of surgery, and safety (NCT01437514). Results: In total, 401 patients were analyzed. With a median 54 months' follow-up, low-risk patients obtained better 3-year cumulative incidence of local recurrence (2.2% vs 11.0%, P = 0.006), overall survival rate (86.9%vs 76.5%, P = 0.002), disease-free survival rate (87.0% vs 67.9%, P < 0.001), and cumulative incidence of distant recurrence (12.5% vs 29.4%, P < 0.001) than high-risk patients. With regard to 3-year cumulative incidence of local recurrence, no differences were observed between the LoR and LoS groups (1.2% vs 3.0%, P = 0.983) or the HiR and HiS groups (12.9% vs 8.9%, P = 0.483). Conclusions and Relevance: Stratification of stage II/III rectal cancers according to risk factors to more precise subclassifications may result in noteworthy differences in survivals and local pelvic control. An extremely low cumulative incidence of local recurrence and survivals in low-risk patients can be achieved with upfront good quality of surgery alone. This trial, owing to the insufficient power, could not prove the noninferiority of surgery alone, but suggest a discriminative use of NRT according to clinical risk stratification in stage II/III rectal cancer.
引用
收藏
页码:1060 / 1069
页数:10
相关论文
共 50 条
  • [31] ARNEO: A Randomized Phase II Trial of Neoadjuvant Degarelix with or Without Apalutamide Prior to Radical Prostatectomy for High-risk Prostate Cancer
    Devos, Gaetan
    Tosco, Lorenzo
    Baldewijns, Marcella
    Gevaert, Thomas
    Goffin, Karolien
    Petit, Valentin
    Mai, Cindy
    Laenen, Annouschka
    Raskin, Yannic
    Van Haute, Carl
    Goeman, Lieven
    De Meerleer, Gert
    Berghen, Charlien
    Devlies, Wout
    Claessens, Frank
    Van Poppel, Hendrik
    Everaerts, Wouter
    Joniau, Steven
    EUROPEAN UROLOGY, 2023, 83 (06) : 508 - 518
  • [32] Bevacizumab and combination chemotherapy in rectal cancer until surgery (BACCHUS): A phase II, multicenter, open-label, randomized study of neoadjuvant chemotherapy alone without radiation in patients with MRI-defined high-risk cancer of the rectum not threatening the circumferential margin
    Harrison, Mark
    Beare, Sandy
    Bridgewater, John A.
    Chau, Ian
    Goh, Vicky
    Mcdonald, Alec
    Melcher, Lucinda
    Moran, Brendan J.
    Osborne, Melanie
    Quirke, Philip
    Wasan, Harpreet
    Wong, Wailup
    Glynne-Jones, Robed
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [33] Risk factors for local recurrence in patients with clinical stage II/III low rectal cancer: A multicenter retrospective cohort study in Japan
    Kozu, Takumi
    Akiyoshi, Takashi
    Sakamoto, Takashi
    Yamaguchi, Tomohiro
    Yamamoto, Seiichiro
    Okamura, Ryosuke
    Konishi, Tsuyoshi
    Umemoto, Yoshihisa
    Hida, Koya
    Naitoh, Takeshi
    ANNALS OF GASTROENTEROLOGICAL SURGERY, 2025, 9 (01): : 128 - 136
  • [34] Neoadjuvant FOLFOX 4 versus FOLFOX 4 with Cetuximab versus immediate surgery for high-risk stage II and III colon cancers: a multicentre randomised controlled phase II trial – the PRODIGE 22 - ECKINOXE trial
    Mehdi Karoui
    Anne Rullier
    Alain Luciani
    Franck Bonnetain
    Marie-Luce Auriault
    Antony Sarran
    Geneviève Monges
    Hervé Trillaud
    Karine Le Malicot
    Karen Leroy
    Iradj Sobhani
    Armelle Bardier
    Marie Moreau
    Isabelle Brindel
    Jean François Seitz
    Julien Taieb
    BMC Cancer, 15
  • [35] Preoperative and postoperative prognostic factors of patients with stage II/III lower rectal cancer without neoadjuvant therapy in the clinical trial (JCOG0212)
    Ohue, Masayuki
    Fujita, Shin
    Mizusawa, Junki
    Kanemitsu, Yukihide
    Hamaguchi, Tetsuya
    Tsukamoto, Shunsuke
    Noura, Shingo
    Yasui, Masayoshi
    Itoh, Masaaki
    Shiomi, Akio
    Komori, Koji
    Watanabe, Jun
    Akazai, Yoshihiro
    Shiozawa, Manabu
    Yamaguchi, Takashi
    Bandou, Hiroyuki
    Katsumata, Kenji
    Moriya, Yoshihiro
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2022, 52 (02) : 114 - 121
  • [36] Early results of phase II trial of perioperative oxaliplatin and capecitabine (XELOX) without radiotherapy for high-risk rectal cancer (CORONA I)
    Uehara, K.
    Nakayama, G.
    Ishigure, K.
    Kobayashi, S.
    Hiramatsu, H.
    Nakayama, H.
    Yamashita, K.
    Sakamoto, E.
    Tojima, Y.
    Kawai, S.
    Kodera, Y.
    Nagino, M.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S333 - S334
  • [37] mFOLFIRINOX versus mFOLFOX 6 as adjuvant treatment for high-risk stage III colon cancer (FROST trial): Study protocol for an open label, multicenter, randomized, phase II study.
    Lee, Kyung-ha
    Kim, Ji Yeon
    Yang, In Jun
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : TPS230 - TPS230
  • [38] Surgery Alone Versus Chemoradiotherapy Followed by Surgery for Stage I and II Esophageal Cancer: Final Analysis of Randomized Controlled Phase III Trial FFCD 9901
    Mariette, Christophe
    Dahan, Laetitia
    Mornex, Francoise
    Maillard, Emilie
    Thomas, Pascal-Alexandre
    Meunier, Bernard
    Boige, Valerie
    Pezet, Denis
    Robb, William B.
    Le Brun-Ly, Valerie
    Bosset, Jean-Francois
    Mabrut, Jean-Yves
    Triboulet, Jean-Pierre
    Bedenne, Laurent
    Seitz, Jean-Francois
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (23) : 2416 - U201
  • [39] Neoadjuvant S-1 and oxaliplatin plus bevacizumab therapy for high-risk locally advanced rectal cancer: A prospective multicenter phase II study
    Miura, Takuya
    Morohashi, Hajime
    Sakamoto, Yoshiyuki
    Kagiya, Takuji
    Hasebe, Tatsuya
    Nakayama, Yoshihito
    Fujita, Hiromasa
    Hakamada, Kenichi
    ANNALS OF GASTROENTEROLOGICAL SURGERY, 2024, 8 (01): : 71 - 79
  • [40] A Phase II/III Randomized Controlled Trial of Adjuvant Radiotherapy, Concurrent Chemoradiotherapy after Surgery Versus Surgery Alone in Patients with Stage IIB-III Esophageal Squamous Cell Carcinoma
    Ni, W.
    Xiao, Z.
    Zhou, Z.
    Wang, X.
    Chen, D.
    Qinfu, F.
    Liang, J.
    Lv, J.
    Bi, N.
    Deng, L.
    Zhang, T.
    Wang, W.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2019, 105 (01): : E193 - E193